By VETTAPHARMA reporter – Derek Roche: GSK announced on June 9, 2026, that it has entered into an agreement to acquire Nuvalent for approximately $10.6 billion, strengthening its oncology pipeline with three lung cancer-focused assets and accelerating its expansion into non-small cell lung cancer (NSCLC). The transaction includes zidesamtinib (NVL-520), a next-generation ROS1 inhibitor, and neladalkib (NVL-655), a next-generation ALK inhibitor. Both investigational therapies have received FDA Breakthrough Therapy and Orphan Drug Designations and are currently under FDA review. Target decision dates are September 18, 2026, for zidesamtinib and November 27, 2026, for neladalkib.
GSK said both candidates have demonstrated potential best-in-class profiles and could launch in 2026 if approved. The acquisition also includes NVL-330, a Phase I HER2 inhibitor for HER2-altered NSCLC, along with Nuvalent’s broader preclinical oncology pipeline.
According to GSK, the acquisition aligns with its strategy of acquiring assets directed at validated targets that address efficacy and tolerability limitations of existing therapies. The company believes the deal will establish a foundation for growth in lung cancer and complement Ris-Rez, its B7-H3 antibody-drug conjugate currently in Phase III development.
Pivotal clinical data presented at the 2025 IASLC World Conference on Lung Cancer and the 2026 ASCO Annual Meeting supported the profiles of zidesamtinib and neladalkib. The therapies are designed to improve selectivity, enhance central nervous system penetration, provide broader mutation coverage, and potentially offer more durable responses than currently available treatments.
Under the merger agreement, GSK will launch a tender offer to acquire all outstanding Nuvalent shares for $124 per share in cash, representing a 40% premium to Nuvalent’s last closing price and a 26% premium to its 30-day volume-weighted average price.
After accounting for acquired cash, GSK estimates its net investment at approximately $9.4 billion (£7.1 billion). The company expects the acquisition to contribute to revenue growth beginning in 2027, support its ambition to exceed £40 billion in annual sales by 2031, and become accretive to core operating profit in 2027 and core earnings per share in 2029.
GSK stated that the transaction will be funded primarily through existing and new debt facilities and is not expected to affect its investment-grade credit rating. The acquisition remains subject to customary closing conditions, including shareholder tender and regulatory approvals.
Quick FAQs
1. What Is Nuvalent?
Nuvalent is a clinical-stage biopharmaceutical company focused on developing precisely targeted cancer therapies designed to overcome limitations of existing kinase inhibitors.
2. What Happened?
GSK entered into an agreement to acquire Nuvalent for approximately $10.6 billion, gaining rights to multiple lung cancer assets, including zidesamtinib, neladalkib, and NVL-330.
3. What Are Zidesamtinib and Neladalkib?
Zidesamtinib (NVL-520) is a ROS1 inhibitor and neladalkib (NVL-655) is an ALK inhibitor for NSCLC. Both are under FDA review with target decision dates in September and November 2026, respectively.
4. What Is Non-Small Cell Lung Cancer?
NSCLC is the most common form of lung cancer and can be driven by genetic alterations such as ALK, ROS1, or HER2 mutations. It frequently spreads to the central nervous system.
5. What Were the Key Data Supporting the Acquisition?
Pivotal data presented at IASLC 2025 and ASCO 2026 showed promising efficacy and safety profiles for zidesamtinib and neladalkib, supporting their potential as best-in-class targeted therapies.
6. Why Is This Important?
The acquisition immediately expands GSK’s oncology pipeline, provides a strategic entry into targeted lung cancer therapies, and adds two late-stage assets with potential commercial launches in 2026 pending FDA approval.
